monoclonal antibodies, MAbs,) for rheumatoid arthritis (RA) -- Disease modifying anti-rheumatic drugs (DMARDs) -- Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and aldose
reductase inhibitors -- Understanding pain pathways and mechanisms of action -- Safety and patient compliance -- Clinical evidence supporting product efficacy
Drugs profile discussed in this report include 2B3-201, adalimumab, ATXUV-1, ATXUV-2, B27-PD, celecoxib, CF-101, Col-Treg, Cytectin, dexamethasone acetate, Dexamethasone Sodium Phosphate-Visulex, Drugs to Inhibit Aldose
Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders, EBI-028, EC-1496, EC-1669, fluocinolone acetonide, FR-104, gevokizumab, HL-036, IBI-70090, IMD-0354, INV-17, LFG-316, lodamin, NOP-3, NS-2, OX-1001, PA-2612, Peptides to Modulate TCR for Uveitis, plastoquinone decyl triphenylphosphonium bromide, PP-001, PPL-003, Recombinant Enzymes for Uveitis, sarilumab, sirolimus, Small Molecules to Inhibit Kinase for Uveitis and Inflammatory Bowel Disease, Stem Cell Therapy for Autoimmune Diseases, triamcinolone acetonide, V-404.
Taking each in turn, the 50 papers discuss such aspects as acetaldehyde elimination changes in transgenic mice lacking aldehyde dehydrogenase 2 activity, the role of carbonyl metabolizing enzymes in the hepatocyte cytotoxicity of chloral hydrate and tribromoethanol anesthetics, and the search for effective aldose